Key result
Higher preoperative levels of IGFBP2 predicted suboptimal surgical outcome after primary debulking surgery with an AUC of 0.796, but it was not an independent risk factor in multivariate analysis (adjusted OR 5.0, p=0.198).
Why the study?
Does preoperative level of IGFBP2 predict suboptimal outcome after primary debulking surgery in patients with advanced ovarian cancer?
Population
24 subjects with advanced ovarian cancer (Stage IIIc/IV) who underwent primary debulking surgery (PDS)
Design
Cohort
Authors
Loading...
IGFBP2 may predict PDS outcomes in AOC; hypothesis-generating and requires prospective validation before any clinical use.
Cohort (n=24)
No
Does preoperative level of IGFBP2 predict suboptimal outcome after primary debulking surgery in patients with advanced ovarian cancer?
Odds Ratio: 5 (95% CI 0.43–57.9)
p-value: p=0.198
Preoperative IGFBP2 level is a promising biomarker for predicting suboptimal surgical outcomes following primary debulking surgery in advanced ovarian cancer.
Prayudi et al. (2023) conducted a cohort in Advance Ovarian Cancer (n=24). Preoperative level of IGFBP2 vs. Lower IGFBP2 level was evaluated on Suboptimal surgical outcome after primary debulking surgery (adjusted OR 5.0, 95% CI 0.43-57.9, p=0.198). Higher preoperative levels of IGFBP2 predicted suboptimal surgical outcome after primary debulking surgery with an AUC of 0.796, but it was not an independent risk factor in multivariate analysis (adjusted OR 5.0, p=0.198).